and Human Services
9000 Rockville Pike
Bethesda, Maryland 20892
ADDENDUM TO RFA-RM-04-018, “NANOMEDICINE CENTER CONCEPT DEVELOPMENT AWARDS” RELEASE DATE: July 1, 2004 NOTICE: NOT-RM-04-013 National Institutes of Health (NIH) (http://www.nih.gov) This notice is an addendum to RFA-RM-04-018, “Nanomedicine Center Concept Development Awards” at (http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-04-018.html) which was released in the NIH Guide for Grants and Contracts on May 4, 2004. It clarifies various issues and requirements related to the Concept Development Memo (CDM), Concept Development Award (CDA), and Concept Development Plan (CDP) described in this RFA. o Letters of collaboration from any investigators who are not employed by the applicant organization should be included with the CDM. o Applicants need not submit the percent level of effort for key personnel. o Information on Other Support should not be included in the CDM. o An institution may submit more than one CDM. o Investigators may be included as key personnel on more than one CDM. o A management plan should be included if multiple institutions are involved. o Individuals who have applied or intend to apply to other RFAs specifically targeted to nanotechnology or nanomedicine are still eligible to submit a CDM. o CDAs will be issued for a period of six months, i.e., until March 31, 2005. Funds may be used for planning activities and may include travel for key personnel to the March, 2005 meeting. No supplements to CDAs will be issued for additional planning or for writing the Centers application. However, if CDA funds remain at the end of the budget period, a four month no-cost extension may be requested. o If a large number of CDMs is received, a triage process will be used to select the most meritorious CDMs for full review. o Applicants will receive two emails. The first will indicate receipt of the CDM and will be sent within two weeks of receipt. The second will provide a brief summary of the review and its outcome. If a CDM is triaged, the second email will not include a review summary. o The abstract of CDAs will be published on the NIH Nanomedicine Roadmap website. The purpose of this posting is to facilitate development of additional collaborations. Investigators interested in collaborating with awardees will be encouraged to contact the awardees. o Each group that receives a CDA may submit a CDP and, in turn, may submit a centers application in July, 2005. CDA applicants who are unsuccessful this fiscal year may not apply for a Nanomedicine Development Center grant in fiscal year 2005. If another round of centers will be funded in FY 2006 as expected, previously unsuccessful applicants would be eligible to reapply. o The Nanomedicine Roadmap plans include funding for additional Centers in fiscal years 2006 ($6M) and 2008 ($13M). Such funds may also be used for expanding the scope of one or more of the Centers funded in 2005, or for supporting interactions within the network of Centers. The CDM may address use of future funding increments. INQUIRIES: Richard S. Fisher, Ph.D. Project Team Leader, Nanomedicine Roadmap Initiative Division of Extramural Research National Eye Institute 5635 Fishers Lane, Room 1300 Bethesda, MD 20892-9300 Telephone: (301) 451-2020 Email: fisherR@mail.nih.gov Support for the NIH Roadmap and its initiatives is provided by all Institutes and Centers, whose representatives direct and oversee each initiative. The National Eye Institute (NEI) is the lead administrative institute for the Nanomedicine Initiative.
Return to NIH Guide Main Index
|
|
Department of Health and Human Services |
|
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |